Effect of Chinese herbal medicine compound on breast hyperplasia
A protocol of systematic review
Hui-lin Guan, MM\textsuperscript{a}, Yu Wang, MM\textsuperscript{b}, Yi-fang Gui, MM\textsuperscript{c}, Chun-lei Zhang, MM\textsuperscript{a,\textsuperscript{*}}

Abstract
Background: Data supporting the use of Chinese herbal medicine compound (CHMC) on breast hyperplasia (BH) based on the data from previous studies. However, the results are still contradictory. Thus, this study aims to compare the results obtained for effect on case-controlled study (CCS) of CHMC on BH.

Methods: This study will include CCS assessing the effect of CHMC on BH. A literature search will be carried out in Cochrane Library, MEDLINE, EMBASE, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception to the present. We will not apply language limitation to any electronic database. Study quality will be evaluated using Newcastle-Ottawa Scale, and statistical analysis will be performed using RevMan 5.3 software.

Results: This study will summarize the up-to-date evidence to assess the effect of CHMC on BH.

Conclusion: The results of this study may exert helpful evidence to determine whether CHMC is effective on BH.

OSF registration number: osf.io/3k8ch.

Abbreviations: BH = breast hyperplasia, CCS = case-controlled study, CHMC = Chinese herbal medicine compound, CIs = confidence intervals.

Keywords: breast hyperplasia, Chinese herbal medicine compound, effect

1. Introduction
Breast hyperplasia (BH) is a very common benign breast condition, with prevalence increasing each year.\textsuperscript{[1–3]} It is usually detected by chance, and it does not manifest any specific symptoms, except lump or pain.\textsuperscript{[4,5]} It usually develops as the breast changes with age, and often occurs in women over 35 years old.\textsuperscript{[6]} Although it is a benign condition, patients with BH have an increased risk of developing breast cancer.\textsuperscript{[7–11]} Thus, it is very important to manage this issue.

Despite lots of studies have reported that Chinese herbal medicine compound (CHMC) can help treat BH,\textsuperscript{[12–26]} there are still not consistent conclusions among those studies. In addition, no systematic review specifically explores this topic. Therefore, this study will firstly and systematically address the effect of CHMC on BH.

2. Methods
2.1. Study registration
This study has been registered on OSF (osf.io/3k8ch). It is reported based on the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.

2.2. Eligibility criteria
2.2.1. Types of studies. Case-controlled study (CCS) will be selected to evaluate the effect of CHMC on BH.

2.2.2. Types of interventions. Intervention: All participants in the experimental group received CHMC for the treatment of BH. Comparator: All participants with BH in the control group were given any management, such as no treatment, and placebo.

2.2.3. Types of subjects. Studies assessing rats which were diagnosed with BH will be included in this study.

2.2.4. Types of outcomes. Outcomes include nipple diameter, mammary gland volume, mammary gland mass, mammary lobule number, acinar number in the lobule, serum estradiol, prolactin level, serum superoxide dismutase activity, serum malondialdehyde, and toxicity.

This study has supported in part by the Basic Research Business Expenses Research Project of Provincial Colleges and Universities in Heilongjiang Province (2018-KYYWF-0202, 2018-KYYWF-0203). The funder had no roles this study.

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

\textsuperscript{*} Correspondence: Chun-lei Zhang, Department of Scientific Research, Mudanjiang Medical University, No.3 Tongxiang Street, Aimin District, Mudanjiang, 157011, China (e-mail: chunleizhang1980@sohu.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Guan HL, Wang Y, Gui YF, Zhang CL. Effect of Chinese herbal medicine compound on breast hyperplasia: A protocol of systematic review. Medicine 2020;99:49(e23463).

Received: 27 October 2020 / Accepted: 2 November 2020
http://dx.doi.org/10.1097/MD.00000000000023463
2.2.5. Information sources. A literature search will be conducted at Cochrane Library, MEDLINE, EMBASE, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure since their inception to the present. No language limitation is applied to all electronic databases. In addition, we will also search conference proceedings, dissertations, and reference lists of included studies. A sample of search strategy for Cochrane Library is presented in Table 1. We will also adapt similar search strategy to other electronic databases.

| Number | Search terms |
|--------|--------------|
| 1      | Mesh descriptor: (postoperative pain) explode all trees |
| 2      | (postoperative) or (pain, postoperative) or (postoperative pain) or (persistent postsurgical pain) or (postoperative) or (post surgery) or (pain intensity) ti, ab, kw |
| 3      | Or 1–2 |
| 4      | Mesh descriptor: (acupuncture) explode all trees |
| 5      | Mesh descriptor: (electroacupuncture) explode all trees |
| 6      | (‘needling’) or (acupoints) or (fire needle) or (auricular needle) or (auriculo-acupuncture) or (ear acupuncture) or (scalp acupuncture) or (dermal needle) or (abdominal acupuncture) ti, ab, kw |
| 7      | Or 4–6 |
| 8      | MeSH descriptor: (randomized controlled trials) explode all trees |
| 9      | (RCT) or (randomly) or (random) or (blind) or (allocation) or (control) or (placebo) or (sham) or (clinical study) or (clinical trials) or (controlled study) or (controlled trial) ti, ab, kw |
| 10     | Or 8–9 |
| 11     | 3 and 7 and 10 |

lateral[ti] AND epicondylitis[ti] AND lateral[ti] AND epicondylitis[ti] AND surgery[ti] OR surgical[ti] AND management[ti] AND percutaneous[ti] AND lateral[ti] AND epicondylitis[ti] AND tennis[ti] AND elbow[ti] AND surgery[ti] AND common[ti] AND extensor[ti] AND release[ti].

2.3. Selection of studies

Before the selection of studies, we will build standard eligibility criteria to identify all searched studies. Two authors will independently scan the titles and abstracts. All irrelevant studies will be excluded, and we will read full texts of remaining studies. We will present process of study selection in a flowchart. Two authors will perform all study selection, respectively. Any different opinions will be solved by consensus with a third author.

2.4. Data extraction and management

Two authors will independently extract data based on the predefined data collection form. It comprises of title, first author, time of publication, study setting, subject characteristics (sample size, age, sex), study methods, intervention and control details (intervention types, dosage, frequency, and duration), outcomes, and funding information. Any disagreements about data extraction will be resolved by discussion with another author.

2.5. Study quality assessment

Two authors will independently evaluate the risk of bias of the retrieved studies using Newcastle-Ottawa Scale. A third author will help to solve any divergences about study quality assessment between 2 authors.

2.6. Statistical analysis

We will perform statistical analysis using RevMan 5.3 software (Cochrane Community, London, UK.). In this study, we will exert continuous data as mean difference and 95% confidence intervals (CIs); and dichotomous data as risk ratio and 95% CIs. We will identify heterogeneity among included studies using $I^2$ statistic. $I^2 \leq 50\%$ indicates acceptable heterogeneity, whereas $I^2 > 50\%$ means indication of obvious heterogeneity, respectively. If acceptable heterogeneity is identified, we will use a fixed-effect model. On the other hand, if substantial heterogeneity is detected, we will utilize a random-effect model. Meanwhile, we will also conduct subgroup analysis to explore the reasons which are responsible for the significant heterogeneity. We will not pool the outcome data and will not carry out meta-analysis if significant heterogeneity still exists after subgroup analysis. Instead, we will report narrative summary description in accordance with the Guidance on the Conduct of Narrative Synthesis in Systematic Reviews.

2.7. Additional analysis

2.7.1. Subgroup analysis. If sufficient studies are included, we will carry out subgroup analysis according to the different study information, treatments, controls, and outcomes.

2.7.2. Sensitivity analysis. When necessary, sensitivity analysis will be performed to identify stability of pooled outcome results by excluding low quality studies.

2.7.3. Reporting bias. If >10 CCS are entered in this study, we will conduct funnel plot and Egger regression test to explore any possible reporting bias.

2.7.4. Ethics and dissemination. This study will not need ethical approval as no primary data will be collected. This study will be disseminated via a peer-reviewed journal or conference meetings.

3. Discussion

In this study, we firstly investigate the effect of CHMC on BH. Only the evidence from eligible CCS will be considered for inclusion. Methodological quality of all included studies will be appraised by 2 authors, respectively. The interpretation of study methodological quality should take their designs, methods, and data analyst into account. The contribution of this study will supply evidence on both external validity of these results, as well as its usage to the clinical practice.
Author contributions

Conceptualization: Hui-lin Guan, Yi-fang Gui, Chun-lei Zhang.
Data curation: Hui-lin Guan, Yu Wang, Yi-fang Gui, Chun-lei Zhang.
Formal analysis: Hui-lin Guan, Yu Wang, Yi-fang Gui, Chun-lei Zhang.
Investigation: Yi-fang Gui.
Methodology: Hui-lin Guan, Yu Wang, Chun-lei Zhang.
Project administration: Yi-fang Gui.
Resources: Hui-lin Guan, Yu Wang, Chun-lei Zhang.
Software: Hui-lin Guan, Yu Wang, Chun-lei Zhang.
Supervision: Yi-fang Gui.
Visualization: Hui-lin Guan, Yu Wang, Yi-fang Gui, Chun-lei Zhang.
Validation: Yi-fang Gui.
Methodology: Hui-lin Guan, Yi-fang Gui, Chun-lei Zhang.
Project administration: Hui-lin Guan, Yu Wang, Chun-lei Zhang.
Software: Hui-lin Guan, Yu Wang, Chun-lei Zhang.
Supervision: Yi-fang Gui.
Visualization: Hui-lin Guan, Yu Wang, Yi-fang Gui, Chun-lei Zhang.
Writing – original draft: Hui-lin Guan, Yu Wang, Yi-fang Gui, Chun-lei Zhang.
Writing – review & editing: Hui-lin Guan, Yu Wang, Chun-lei Zhang.

References

[1] Xin ZF. Classification and treatment of breast hyperplasia. Chin J Breast Dis 2008;2:689–94.
[2] Lan GH, Wu CH, Wu CY. Breast lobular hyperplasia and personality. Chin Ment Health J 1997;11:342.
[3] Gao XF, Wang B, Lu XK, et al. Advances in research on the psychological disorders among patients with breast hyperplasia. J Zhejiang Chun Med Univ 2012;36:849–51.
[4] Huang XJ, Luo RH, Xu XJ, et al. Relationship between breast hyperplasia and stress. Health Psychol J 2000;8:182–3.
[5] Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275–85.
[6] Danforth DN. Molecular profile of atypical hyperplasia of the breast. Breast Cancer Res Treat 2018;167:9–29.
[7] Danforth DN. Genomic changes in normal breast tissue in women at normal risk or at high risk for breast cancer. Breast Cancer (Auckl) 2016;10:109–46.
[8] Sewell CW. Pathology of high-risk breast lesions and ductal carcinoma in situ. Radiol Clin North Am 2004;42:821–30.
[9] Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:496–51.
[10] Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229–37.
[11] Co M, Kwong A, Shek T. Factors affecting the under-diagnosis of atypical ductal hyperplasia diagnosed by core needle biopsies - a 10-year retrospective study and review of the literature. Int J Surg 2018;49:27–31.
[12] Chen X, Liu D, Yue F, et al. Study on the effect mechanism of Sanjieling capsules on breast hyperplasia. Mod J Integr Trad Chin Western Med 2019;28:1163–8.
[13] Lin T, Gu Y, Ma J, et al. Experimental research progress in the treatment of mammary gland hyperplasia with Chinese herbal compound. China Pharma 2017;26:1–4.
[14] Zhao YR, Chen Y, Bing FH. Treatment of 24 cases of breast nodules with Chinese herbal compound. Forum Primary Med 2016;20:1405–6.
[15] Ding XW, Fang Y. Clinical observation on 120 cases of breast addiction treated with traditional Chinese medicine compound Neixiaorutong Decoction. Global Chin Med 2014;7:378–8.
[16] Zhang HL. 132 cases of breast hyperplasia treated with traditional Chinese medicine. Jiangsu Trad Chin Med 2009;41:49.
[17] Liu XH, Ji XK. The effect of Chinese herbal compound combined with tamoxifen on the expression of ER and PR in experimental rat mammary glands. Qilu Pharma Aff 2007;7:424–6.
[18] Wang YT, She YF, Wang HS, et al. The effect of Ru Zengkang on the pathological tissue model of rat mammary hyperplasia. J Beijing Univ Trad Chin Med 2003;5:51–3.
[19] Miao N, Wang Q, Wang SS, et al. External use of the screening prescription for mammary gland lobular hyperplasia on the estrous cycle of rats with mammary hyperplasia. Chin J Trad Chin Med 2020;35:3142–5.
[20] Li JM, Liu JX, Xing ZT, et al. Effect of Rujuxiao granules on model rats with liver depression and qi stagnation type mammary gland hyperplasia. N Chin Med Clin Pharmaco 2020;31:627–36.
[21] Jiang BX, Guo HM, Jiao LN, et al. Anti-hyperplasia effect of Xiangshu Pills in rats and its regulation mechanism on sex hormones. N Chin Med Clin Pharmaco 2020;31:546–52.
[22] Guan HL, Wang Y, Liu Y. The effect of traditional Chinese medicine prescription JNRK on mammary hyperplasia rats. J Mudanjiang Med Col 2020;41:42–4.
[23] Zhang TT, Wang P, Zhang JW. Effects of Ruxiaojiao III modified recipe on hemorheology and PCNA expression in mammary hyperplasia model rats. Fujian Trad Chin Med 2020;31:51–3.
[24] Miao N, Wang Q, Che JM, et al. The effect of external use of the screening prescription for mammary gland lobular hyperplasia on mammary gland tissue pathology and sex hormone receptors in rats with mammary gland hyperplasia. Mod J Integr Trad Chin Western Med 2020;29:115–9.
[25] Ye YC, Ding GH, Ma ZJ, et al. Effects of Ruku Capsule on the expression of mammary gland tissue and related receptors in rats with hyperplasia of mammary glands. N Chin Med Clin Pharmacol 2020;31:627–36.
[26] Tang H, Chen LJ, Yue F, et al. Serum metabonomics study of the mechanism of Xiaoruzeng capsule in the treatment of mouse mammary gland hyperplasia. Pharmacol Clin Chin Mater Medica 2019;35:3142–5.
[27] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[28] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.